Generic Name : Ruxolitinib
International- Jakafi. Why it is prescribed (Indications) :
This medication is a kinase inhibitor, prescribed for high-risk myelofibrosis. It blocks certain substances (JAK1 and JAK2) that are involved in myelofibrosis. When it is not to be taken (Contraindications): Contraindicated in patients with known hypersensitivity.
Dosage & When it is to be taken :
PO- The starting dose is 20 mg 2 times per day, for patients with platelet count greater than 200 X 109/L. How it should be taken :
It comes as a tablet to take by mouth, with or without food. Warnings and Precautions :
* Caution should be exercised in patients with history of liver or kidney impairment, patients on dialysis, during pregnancy and breastfeeding.
* It may cause dizziness, avoid performing any hazardous activity while taking this medication.
* Patient may develop with certain types of infection; discuss with your healthcare provider before taking this medication.
* It may reduce platelet counts; avoid injury or bruising.
* Monitor complete blood count regularly while taking this medication. Side Effects :
Most Frequent - Thrombocytopenia and anemia.
Miscellaneous - Bruising, dizziness, headache, urinary tract infection, weight gain, flatulence, herpes zoster.
* Avoid excess dosage. Storage Conditions :
Store it at room temperature (20° to 25°C).
Comment & Contribute
Ask an Expert